Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896427 | 0.88 | BRD4 (0.31) | BRD4 | |
| SCHEMBL5896460 | 0.88 | BRD4 (0.31) | BRD4 | |
| SCHEMBL5896578 | 0.85 | MEN1 (0.31) | BRD4KMT2A | |
| SCHEMBL5896693 | 0.85 | NPY5R (0.34) | MAPTKMT2A | |
| SCHEMBL5896560 | 0.84 | FLT1 (0.34) | BRD4 | |
| SCHEMBL5897529 | 0.84 | KCNH2 (0.31) | KMT2A | |
| SCHEMBL5896961 | 0.84 | FLT1 (0.34) | BRD4 | |
| SCHEMBL5897492 | 0.84 | KCNH2 (0.31) | KMT2A | |
| SCHEMBL5896348 | 0.84 | KCNH2 (0.37) | BRD4MAPTKMT2A | |
| SCHEMBL3070588 | 0.83 | TP53 (0.38) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030144-B2 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-04-18 | — | — | US | claimed |
| EP-1499608-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION | 2004-01-01 | — | — | US | claimed |
| WO-2003093263-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1499608-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093263-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | GABRA1, GABRA3, GABRA2 | BRD4 1322/4885MAPT 495/4885ALOX5AP 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.